Evolus
EOLS • NASDAQ
Evolus is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO David Moatazedi, with a market cap of $358.5M.
CEODavid Moatazedi
Market Cap$358.5M
Drug Manufacturers - Specialty & Generic
Healthcare
Employees279.0
Websiteevolus.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Evolus
Date
Wednesday, May 6, 2026 (in 2 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.10
Revenue Estimate
$72.2M
Earnings History
Past 12 earnings reports for Evolus
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | Q4 2025 | $0.05Est: $0.01 | +400.0% | $90.3MEst: $89.5M | +0.9% |  10-K |
| Nov 5, 2025 | Q3 2025 | -$0.11Est: -$0.21 | +47.6% | $69.0MEst: $67.6M | +2.1% | 10-Q |
| Aug 5, 2025 | Q2 2025 | -$0.23Est: -$0.13 | -76.9% | $69.4MEst: $82.4M | -15.8% | 10-Q |
| May 7, 2025 | Q1 2025 | -$0.15Est: -$0.01 | -1400.0% | $68.5MEst: $75.4M | -9.1% | 10-Q |
| Mar 4, 2025 | Q4 2024 | $0.04Est: $0.04 | 0.0% | $78.9MEst: $78.3M | +0.9% | 10-K |
| Nov 6, 2024 | Q3 2024 | -$0.17Est: -$0.10 | -70.0% | $61.1MEst: $62.2M | -1.9% | 10-Q |
| Jul 31, 2024 | Q2 2024 | -$0.04Est: -$0.03 | -33.3% | $66.9MEst: $66.2M | +1.0% | 10-Q |
| May 7, 2024 | Q1 2024 | -$0.08Est: -$0.10 | +20.0% | $59.3MEst: $57.3M | +3.5% | 10-Q |
| Mar 7, 2024 | Q4 2023 | -$0.12Est: -$0.07 | -71.4% | $61.0MEst: $60.1M | +1.6% | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.16Est: -$0.17 | +5.9% | $50.0MEst: $45.0M | +11.1% | — |
| Aug 2, 2023 | Q2 2023 | -$0.19Est: -$0.22 | +13.6% | $49.3MEst: $64.1M | -23.0% | 10-Q |
| May 9, 2023 | Q1 2023 | -$0.15Est: -$0.15 | 0.0% | $41.7MEst: $40.7M | +2.5% | — |